Nicholas Donoghoe insider trades: AbbVie (ABBV) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Nicholas reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 5, 2025 | ABBV | ↓ Sell | 13,295 | $198.51 | $2.6M | Direct | Aug 7, 2025 (2d) |
| Mar 20, 2024 | ABBV | ↓ Sell | 21,082 | $176.30 | $3.7M | Direct | Mar 22, 2024 (2d) |
| Dec 26, 2023 | ABBV | ↓ Sell | 2,912 | $154.72 | $451K | Direct | Dec 28, 2023 (2d) |
| Aug 29, 2019 | ABBV | ↑ Buy | 7,525 | $66.19 | $498K | Direct | Aug 30, 2019 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ABBV insiders
Open-market trades in the last 12 months
About Nicholas Donoghoe's insider trades
Nicholas Donoghoe is EVP, Chief Bus/Strat Officer at AbbVie (ABBV). Since Aug 29, 2019, Nicholas has reported 1 open-market purchase worth $498K and 3 sales worth $6.8M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (6 filings), shares withheld for taxes (5 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ABBV insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.